Literature DB >> 9477226

Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone).

A Mordente1, G E Martorana, G Minotti, B Giardina.   

Abstract

Idebenone [2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone] is a synthetic analogue of coenzyme Q that is currently employed in the treatment of vascular and degenerative diseases of the central nervous system. There is some evidence to suggest that idebenone might function as an antioxidant; however, it has not been demonstrated whether this function pertains to the quinone or hydroquinone form of idebenone. Here we demonstrate that idebenone can scavenge a variety of free radical species, including organic radicals such as 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) and diphenylpicrylhydrazyl, peroxyl and tyrosyl radicals, and peroxynitrite. Idebenone can also redox couple with hypervalent species of Mb or Hb, thus preventing lipid peroxidation promoted by these species. Likewise, idebenone inhibits microsomal lipid peroxidation induced by ADP-iron complexes or organic hydroperoxides. In so doing, idebenone prevents the destruction of cytochrome P450, which otherwise would accompany lipid peroxidation. Irrespective of the experimental system under investigation, idebenone functions by virtue of the electron-donating properties of the hydroquinone form. Redox coupling of this hydroquinone with free radicals generates the quinone compound, which per se lacks antioxidant activity. In many experiments, the antioxidant effects of idebenone become appreciable at approximately 2 microM, which is well in the range of plasma levels attainable in patients given oral doses of this drug. Moreover, comparative experiments have shown that the antioxidant efficiency of idebenone varies from no less than 50% to slightly more than 100% of that of vitamin E or Trolox. We would therefore propose that the neuroprotective effects of idebenone can be attributed, at least in part, to its ability to function as an antioxidant, involving redox cycling between hydroquinone and quinone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477226     DOI: 10.1021/tx970136j

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  30 in total

1.  A Strategy for Suppressing Redox Stress within Mitochondria.

Authors:  Pablo M Arce; Omar M Khdour; Ruth Goldschmidt; Jeffrey S Armstrong; Sidney M Hecht
Journal:  ACS Med Chem Lett       Date:  2011-05-31       Impact factor: 4.345

2.  Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.

Authors:  Berthold Pemp; Karl Kircher; Andreas Reitner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-09-03       Impact factor: 3.117

3.  A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model.

Authors:  Piyush M Vyas; Wendy J Tomamichel; P Melanie Pride; Clifford M Babbey; Qiujuan Wang; Jennifer Mercier; Elizabeth M Martin; R Mark Payne
Journal:  Hum Mol Genet       Date:  2011-11-23       Impact factor: 6.150

Review 4.  Recent developments in the drug treatment of Alzheimer's disease.

Authors:  J J Sramek; N R Cutler
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

5.  Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone.

Authors:  Bei Li; Zhi-Qiang Ge
Journal:  AAPS PharmSciTech       Date:  2012-01-11       Impact factor: 3.246

6.  Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model.

Authors:  A R Fetoni; S L M Eramo; R Rolesi; D Troiani; G Paludetti
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-04       Impact factor: 2.124

7.  Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells.

Authors:  Kwok-Keung Tai; L Pham; D D Truong
Journal:  Neurotox Res       Date:  2011-05-03       Impact factor: 3.911

8.  Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia.

Authors:  K V Voronkova; M N Meleshkov
Journal:  Neurosci Behav Physiol       Date:  2009-06

Review 9.  Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease.

Authors:  Maria Laura Bolognesi; Andrea Cavalli; Carlo Melchiorre
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  Idebenone: A Review in Leber's Hereditary Optic Neuropathy.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.